An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

Trial Profile

An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 14 May 2015

At a glance

  • Drugs Mifepristone (Primary)
  • Indications Cushing syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms SEISMIC
  • Sponsors Corcept Therapeutics
  • Most Recent Events

    • 14 May 2015 According to a Corcept Therapeutics media release, data from this study was presented in the posters at the 24th annual American Association of Clinical Endocrinologists in May 2015.
    • 05 Mar 2015 According to a Corcept Therapeutics media release, data from this study were presented at the 97th annual Endocrine Society Meeting (ENDO 2015).
    • 19 Jun 2014 According to a Corcept Therapeutics media release, data from this study will be presented at the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top